Clinical Trial Watch

• Sunitinib Plus Prednisone In Patients With Metastatic Hormone-Refractory Prostate Cancer After Failure Of Docetaxel ChemotherapySponsor(s): Pfizer
Identifier: NCT00676650

• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate CancerSponsor(s): Bristol-Myers Squibb
Identifier: NCT00744497

• Soy Protein/Isoflavones and Venlafaxine in Treating Hot Flashes in Patients Receiving Hormone Therapy for Prostate CancerSponsor(s): Wake Forest University, the National Cancer Institute
Identifier: NCT00354432

• Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate CancerSponsor(s): Eastern Cooperative Oncology Group, National Cancer Institute
Identifier: NCT00309985

• Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone TherapySponsor(s): Southwest Oncology Group; National Cancer Institute (NCI)
Identifier: NCT00134056

• Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast CancerSponsor(s): Radiation Therapy Oncology Group, National Cancer Institute
Identifier: NCT00365105

• Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate CancerSponsor(s): Radiation Therapy Oncology Group, National Cancer Institute, Cancer and Leukemia Group B
Identifier: NCT00567580

• Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone MetastasesSponsor(s): Cancer and Leukemia Group B, National Cancer Institute, Southwest Oncology Group, Eastern Cooperative Oncology Group, NCIC Clinical Trials Group
Identifier: NCT00079001

• Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate CancerSponsor(s): Sanofi-Aventis, Regeneron Pharmaceuticals
Identifier: NCT00519285

• A Phase III Trial of ZD4054 (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate CancerSponsor(s): AstraZeneca
Identifier: NCT00617669

• Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate CancerSponsor(s): Celgene Corporation
Identifier: NCT00988208

• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based ChemotherapySponsor(s): Medivation, Inc.
Identifier: NCT00974311

• Study of Immunotherapy to Treat Advanced Prostate CancerSponsor(s): Bristol-Myers Squibb
Identifier: NCT00861614

• A Phase III Study of Alpharadin (Radium-223) in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal MetastasesSponsor(s): Algeta ASA
Identifier: NCT00699751

• Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone InvolvementSponsor(s): Cancer and Leukemia Group B, National Cancer Institute
Identifier: NCT00869206

• Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate CancerSponsor(s): M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Identifier: NCT00024167

• Multicenter Clinical Study of the Sonablate 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFUSponsor(s): USHIFU, LLC
Identifier: NCT00770822

• Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate CancerSponsor(s): Dana-Farber Cancer Institute; Sanofi-Aventis
Identifier: NCT00116142

• Chemotherapy After Prostatectomy (CAP) For High Risk Prostate CarcinomaSponsor(s): Department of Veterans Affairs; Sanofi-Aventis
Identifier: NCT00132301

• A Study of Degarelix in Patients With Prostate CancerSponsor(s): Ferring Pharmaceuticals
Identifier: NCT00928434

• A Trial of Degarelix in Patients With Prostate CancerSponsor(s): Ferring Pharmaceuticals
Identifier: NCT00946920

• Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone MetastasesSponsor(s): University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI); Cancer and Leukemia Group B
Identifier: NCT00698308

• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract CancerSponsor(s): Cancer and Leukemia Group B; National Cancer Institute (NCI)
Identifier: NCT00942331